Regulation of hepatic phase-II metabolism in pregnant mice

Xia Wen, Ajay C. Donepudi, Paul E. Thomas, Angela L. Slitt,
Roberta S. King, and Lauren M. Aleksunes

Department of Pharmacology and Toxicology, Rutgers University Ernest Mario School of Pharmacy, Piscataway, NJ (XW, LMA, Primary Laboratory of Origin)

Department of Biomedical and Pharmaceutical Science, University of Rhode Island, Kingston, RI (ACD, ALS, RSK)

Department of Chemical Biology, Rutgers University Ernest Mario School of Pharmacy, Piscataway, NJ (PET)

Environmental and Occupational Health Sciences Institute, a Joint Institute of Robert Wood Johnson Medical School and Rutgers University, Piscataway, NJ (PET, LMA)
Running Title: Phase-II metabolism in pregnant mice

Send Correspondence to: Lauren Aleksunes, Pharm.D., Ph.D., Dept of Pharmacology and Toxicology, Rutgers University, 170 Frelinghuysen Rd. Piscataway, NJ, 08854 USA, Phone: (848) 445-5518 Fax: (732) 445-0119 E-mail: aleksunes@ehsi.rutgers.edu

Number of Pages: 33
Number of Tables: 1
Number of Supplementary Tables: 1
Number of Figures: 5
Number of References: 55
Number of Words in Abstract: 234
Number of Words in Introduction: 519
Number of Words in Discussion: 1424

Non-Standard Abbreviations
AhR, aryl hydrocarbon receptor; APAP, acetaminophen; β-actin, beta-actin; bDNA, branched DNA; BPA, bisphenol A; CAR, constitutive androstane receptor; Cyp, cytochrome P450; ERα, estrogen receptor alpha; GD, gestation days; Gsts, glutathione S-transferases; HPLC, high-performance liquid chromatography; HNF4α, hepatocyte nuclear factor 4 alpha; Nqo1, NAD(P)H:quinone oxidoreductase 1; Nrf2, nuclear factor e2-related factor 2; PAPS, 3’-phosphoadenosine-5’-phosphosulfate; PND, postnatal days; Pgc-1α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PPARα, peroxisome proliferator-activated receptor alpha; PXR, pregnane X receptor; qPCR, quantitative PCR; Sults, sulfotransferases; UDPGA, uridine 5’-diphosphoglucuronic acid; Ugts, UDP-glucuronosyltransferases; V, virgin controls
Abstract

Phase-II enzymes, including Ugts, Sults, and Gsts, are critical for the disposition and detoxification of endo- and xenobiotics. In this study, the mRNA and protein expression of major phase-II enzymes, as well as key regulatory transcription factors, were quantified in livers of time-matched pregnant and virgin control C57BL/6 mice on gestation days (GD) 7, 11, 14, 17, and postnatal days (PND) 1, 15, and 30. Compared to virgin controls, the mRNA expression of Ugt1a1, 1a6, 1a9, 2a3, 2b1, 2b34, and 2b35 decreased 40 to 80% in pregnant dams. Protein expression of Ugt1a6 also decreased and corresponded with reduced in vitro glucuronidation of bisphenol A in S9 fractions from livers of pregnant mice. Similar to Ugts levels, Gsta1 and a4 mRNAs were reduced in pregnant dams in mid- to late-gestation however no change in protein expression was observed. Conversely, Sult1a1, 2a1/2, and 3a1 mRNAs increased 100 to 500% at various time points in pregnant and lactating mice and corresponded with enhanced in vitro sulfation of acetaminophen in liver S9 fractions. Coinciding with maximal decreases in Ugts as well as increases in Sults, the expression of transcription factors CAR, PPARα, and PXR and their target genes were down-regulated, while ERα mRNA was up-regulated. Collectively, these data demonstrate altered regulation of hepatic Phase-II metabolism in mice during pregnancy and suggest that CAR, PPARα, PXR and ERα signaling pathways may be candidate signaling pathways responsible for these changes.
Introduction

Phase-II enzymes, including UDP-glucuronosyltransferases (Ugts), sulfotransferases (Sults), and glutathione S-transferases (Gsts), detoxify various endo- and xenobiotics to more hydrophilic compounds that are excreted in bile and urine. Phase-II enzymes are mainly expressed in the liver, with some isoforms also expressed in the gastrointestinal tract, kidneys, and adipose tissue (Bock, 2010; Alnouti and Klaassen, 2011). The regulation of Phase-II enzyme expression is complex and involves multiple signaling mechanisms. It is becoming increasingly evident that gender-specific hormones and diurnal patterns of hormone secretion are important in regulating Phase-II enzymes. For example, livers of female mice predominantly express Ugt1a1 and 1a5 mRNA and livers of male mice predominantly express Ugt2b1 mRNA (Buckley and Klaassen, 2009b). Gender divergent expression of specific Ugt isoforms is largely due to different patterns of growth hormone secretion between male and female mice. Likewise, Sult1a1, 1d1, and 2a1/2 mRNAs exhibit female-predominant expression in liver because of the suppressive effects of androgens and growth hormone secretion in male mice (Alnouti and Klaassen, 2011). Therefore, up- or down-regulation of Phase-II enzymes by fluctuations in sex hormones may be important during periods such as pregnancy (Luquita et al., 2001; Sweeney et al., 2006; Papacleovoulou et al., 2011).

During pregnancy, there are a number of maternal physiological alterations including elevated levels of female sex steroid hormones, such as estradiol and progesterone, as well as changes in the metabolism of lipids and cholesterol (Belo et al., 2004; Freemark, 2006; Papacleovoulou et al., 2011). Fluctuations in hormone levels and lipid metabolism during pregnancy may alter the activity of hepatic nuclear receptors that control the expression of Phase-II enzymes. In general,
Phase-II enzymes are cross-regulated by a group of transcription factors including the aryl hydrocarbon receptor (AhR), constitutive androstane receptor (CAR), peroxisome proliferator-activated receptor alpha (PPARα), pregnane X receptor (PXR) as well as the estrogen receptor alpha (ERα) (Bock, 2010; Tolson and Wang, 2010; Alnouti and Klaassen, 2011; Aleksunes and Klaassen, 2012). In addition, the hepatic transcription factors, nuclear factor e2-related factor 2 (Nrf2) and hepatocyte nuclear factors (HNF), are also involved in coordinately regulating Phase-II enzymes (Aleksunes and Manautou, 2007).

Previous studies have demonstrated decreased hepatic nuclear receptor expression in pregnant mice and rats that corresponds with down-regulation of several metabolic enzymes as well as hepatobiliary transporters (Jeong, 2010; Milona et al., 2010; Papacleovoulou et al., 2011). However, a systematic mRNA profiling of Phase-II enzyme isoforms and regulatory transcription factors at multiple time points during pregnancy and lactation in mice is lacking. Therefore, in the present study, the mRNA and protein expression of conjugation enzymes, as well as potential regulatory transcription factors, were quantified in livers of time-matched pregnant and virgin control C57BL/6 mice throughout pregnancy and lactation. Using bisphenol A (BPA) and acetaminophen (APAP) as marker substrates, Phase-II enzyme activities were also assessed in S9 fractions from livers of virgin control and pregnant mice at gestation days (GD) 14 and 17. Mice were selected for this study because of their increasing use in reproductive and developmental toxicology. Understanding the transcriptional regulation of Phase-II enzymes may guide prescribing of drugs during pregnancy to prevent excessive fetal exposure to harmful chemicals and avoid maternal toxicities.
Materials and Methods

APAP, BPA, uridine 5′-diphosphogluconic acid (UDPGA, purity >99%) and 3′-phosphoadenosine-5′-phosphosulfate (PAPS, purity >60%) were purchased from Sigma Chemical Co. (St. Louis, MO). BPA-glucuronide was obtained from Toronto Research Chemicals Inc. (Toronto, Canada). Authentic APAP standards were kindly provided by McNeil-PPC, Inc (Fort Washington, PA) in collaboration with Dr. José Manautou at the University of Connecticut. Other chemicals and reagents were obtained from Sigma Chemical Co.

Animals. Adult female and male C57BL/6 mice (Charles River Laboratories, Inc., 027 strain, Wilmington, MA) were mated overnight and males were removed the following morning. This time point represented GD0. Mice were provided food and water ad libitum. On GD 7, 11, 14, 17 and postnatal days (PND) 1, 15, and 30, serum and liver were collected from pregnant mice and time-matched virgin controls (V). Parturition occurred between GD19 and 21. Pups were housed with dams until weaning on PND21. Livers were harvested and snap frozen in liquid nitrogen. Tissues were stored at -80°C until use. The Institutional Animal Care and Use Committees at Rutgers University and the University of Kansas Medical Center approved these studies.

RNA isolation and messenger RNA quantification. Total RNA from livers of virgin control, pregnant, and lactating mice was isolated using RNABee reagent (Tel-Test Inc., Friendswood, TX) according to the manufacturer’s protocol. Concentrations of total RNA were quantified by Nanodrop spectrophotometry (Pittsburgh, PA, Fisher Sci) at 260 nm.
Messenger RNA was quantified either by branched DNA (bDNA) signal amplification (Buckley and Klaassen, 2007; Petrick and Klaassen, 2007; Cui et al., 2010; Alnouti and Klaassen, 2011) or quantitative real-time PCR (qPCR) depending on the availability and specificity of primers. The mRNA expression of mouse Ugt1a1, 1a5, 1a9, 2a3, 2b1, 2b5, 2b34 and 2b35, Sult1a1, 1d1, 2a1/2 and 3a1, Gsta1, a4, m2 and p1, transcription factors and their target genes including AhR, cytochrome P450 1a1 (Cyp1a1), CAR, Cyp2b10, PPARα, Cyp4a14, PXR and Cyp3a11 was quantified using the bDNA signal amplification assay (Panomics QuantiGene, High Volume bDNA Signal Amplification Kit 1.0; Affymetrix, Santa Clara, CA). Multiple oligonucleotide probe sets (containing capture, label, and blocker probes) specific to mouse mRNA transcripts were designed using ProbeDesigner software (version 1.0; Bayer Corp., Diagnostics Div., Tarrytown, NY).

The hepatocyte nuclear factor 4-alpha (Hnf4α), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (Pgc-1α) as well as ERα, estrogen receptor beta and progesterone receptor were quantified by qPCR. Complimentary DNA (cDNA) was generated with the First Strand SuperScript cDNA synthesis kit (Invitrogen, Carlsbad, CA). Specific forward and reverse primers (Integrated DNA Technologies, Coralville, IA) for each gene (Supplementary Table 1) were added to one microgram of cDNA from each sample. Sybr Green (Applied Biosystems, Carlsbad, CA) was used for detection of amplified products. qPCR was performed in a 384-well plate format using the ABI 7900HT PCR system (Applied Biosystems). The threshold cycle (Ct) value was converted to delta delta Ct values by normalizing to beta-actin (β-actin).
Western blot analysis. Mouse livers from virgin and pregnant mice at GD14 and 17 were homogenized in buffer containing 10 mM Tris-base and 150 mM sucrose (pH 7.5). Protein concentrations were determined using the BCA protein assay kit (Pierce Biotechnology, Rockford, IL). Homogenates (50 μg) were separated by electrophoresis on 4-12% NuPAGE Novex Bis-Tris gels (Invitrogen, Carlsbad, CA), then transferred to polyvinylidene fluoride membranes and blocked with 5% nonfat dry milk in 0.5% PBST (PBS buffer with 0.5% Tween-20) for 1 h. Membranes were incubated with primary antibodies to Ugt1a1 (AB62600), 1a6 (AB97646), 2b10 (AB57685), Sult1a1 (AB57849), Nqo1 (AB2346) (Abcam, Cambridge, MA); Ugt1a9 (H00054600-B01P) (Abvona, Walnut, CA); Sult2a1 (SC-32942), Cyp4a14 (SC-46087) (Santa Cruz, Santa Cruz, CA); Gsta1 (T3370) (Epitomics, Burlingame, CA); Gsta4 (SAB1401164) (Sigma, St. Louis, MO); Cyp2b10 (AB9916), Cyp3a11 (MAB10041) (EMD Millipore, Billerica, MA); Cyp1a1 (C1+C4, from Dr. Paul E. Thomas) for 1 to 2 h. After washing with 0.5% PBST, membranes were incubated with species-appropriate secondary antibodies for 1 h. Membranes were incubated with SuperSignal West Dura Chemiluminescent Substrate (Thermo Scientific, Pittsburgh, PA). Relative band intensities were quantified using a FluorChem Imager (Alpha Innotech, San Leandro, CA) and normalized to levels of β-actin protein (Abcam, Cambridge, MA). Of note, primary antibodies against mouse Ugt1a5, 2a3, 2b1, 2b5, 2b34, 2b35, Sult3a1, 1d1, and Gstm1, p1 proteins were not commercially available.

Isolation of liver S9 fractions. Mouse livers from virgin and pregnant mice at GD14 and 17 were homogenized in homogenizing buffer (50 mM Tris-HCl, 1.15% KCl, pH 7.4) and centrifuged at 9,000 x g for 20 min. Supernatants (S9 fraction) were stored at -80°C until use in in vitro enzyme assays.
**In vitro BPA glucuronidation assay.** S9 fractions (15 μg) were incubated with 1 μM BPA and 2 mM UDPGA in 100 μl of 20 mM phosphate buffer (pH 7.0) at 37°C for 30 min. At the end of the incubation, samples were heated in boiling water to deactivate enzyme activity and centrifuged at 14,000 x g for 10 min. Supernatants were collected and subjected to high performance liquid chromatography (HPLC).

**In vitro APAP glucuronidation and sulfation assays.** For glucuronidation of APAP, the incubation mixture contained mouse liver S9 fractions (100 μg protein), 10 mM MgCl₂, 1 mM UDPGA, alamethicin (25 μg/mg protein) and 2 mM APAP (dissolved in methanol, final concentration 0.2%) in 200 μl of 50 mM Tris buffer (pH 7.4) as described previously (Wen and Walle, 2006). After 30-120 min incubation at 37°C, reactions were terminated by addition of 200 μl of cold HPLC-grade methanol. For sulfation of APAP, 2 mM of APAP was incubated at 37°C for 30 min with mouse liver S9 fractions (100 μg) in 200 μl of 50 mM Tris buffer (pH 7.4) containing 0.0625% bovine serum albumin, 8 mM dithiothreitol, and 0.1 mM PAPS (Wen and Walle, 2006). Reactions were terminated by addition of 200 μl of cold HPLC-grade methanol and samples were centrifuged at 14,000 x g for 2 min. To quantify APAP-glucuronide and APAP-sulfate formation, supernatants were subjected to HPLC.

**HPLC analysis.** BPA and BPA-glucuronide were analyzed using HPLC-UV (System Gold®, Beckman Coulter, Inc.). Each sample (50 μl) was injected into a ZORBAX SB-Aq column (5μm, 4.6X150mm, Agilent Technologies). A gradient elution with 80% acetonitrile and 20% 20 mM phosphate buffer (pH 2.5) at a 1 ml/min flow rate was used. BPA and BPA-glucuronide were identified using standards of BPA and BPA-glucuronide dissolved in 20 mM phosphate buffer.
(pH 7.0). The UV wavelength for BPA and BPA-glucuronide was 200 nm. Quantitation was achieved by comparing the detected peak area to a standard curve.

For APAP glucuronide and sulfate analysis, all samples were analyzed by reverse-phase HPLC system based on previously described methods with modifications (Lickteig et al., 2007; Reisman et al., 2009). The HPLC system (Shimadzu CTO-6A) was equipped with a UV detector (Shimadzu SPND-6A) and an Eclipse XDB-C18 column (4.6mm X 15cm, 3.5 μm). The UV wavelength for APAP and its conjugates was 254 nm. The flow rate was 1 ml/min. Mobile phase A contained 8% methanol and 1% acetic acid in water, and mobile phase B contained 50% methanol in water. The initial running condition for HPLC was 100% mobile phase A. The following time and percent of mobile phase B were: 5 min (0%); 15 min (25%); 20 to 30 min (100%). Quantitation was achieved by comparing the detected peak area to an APAP standard curve (Howie et al., 1977).

**Data analysis.** Messenger RNA data were normalized to time-matched virgin controls at each time point (set to 1.0). All data were expressed as mean ± S.E. (n=3–4, for enzyme activity assay n=5–6). Differences between virgin and pregnant mice of mRNA and protein levels were evaluated by unpaired t-tests at each time point and p values ≤ 0.05 were considered statistically significant using GraphPad Prism software (version 5; GraphPad Software Inc., San Diego, CA).
Results

**Hepatic Ugt expression and function during pregnancy and lactation.** Nine Ugt isoforms (Ugt1a1, 1a5, 1a6, 1a9, 2a3, 2b1, 2b5, 2b34 and 2b35) were selected based upon their moderate to high basal expression in female mouse livers (Buckley and Klaassen, 2009b). Ugt mRNA expression was quantified in time-matched pregnant and virgin control C57BL/6 mice on GD7, 11, 14, 17, and PND1, 15, and 30 (Fig 1A, Table 1). Compared to virgin controls, the mRNA expression of Ugt1a1, 1a6, 1a9, 2a3, 2b1, 2b34 and Ugt2b35 was decreased by 40% to 80% in pregnant dams, with prominent down-regulation on GD14 and 17. In pregnant dams, mRNA expression of Ugt1a5 increased by 50% to 100% compared to virgin controls. The mRNA expression of most Ugts isoforms returned to control levels by mid- to late lactation, except for Ugt1a9 and 2b35, which remained decreased. Levels of Ugt2b5 mRNA were not changed significantly at any time point.

Because the most remarkable changes in mRNA expression occurred on GD14 and 17, protein expression of select Ugt isoforms was quantified at these time points (Fig 1B). Protein expression of Ugt1a1 and 1a9 decreased slightly (about 20%) on GD17 whereas Ugt1a6 was significantly down-regulated by 40%. No change in Ugt2b34 protein was observed at either time point.

BPA is primarily glucuronidated by UGT2B15 in human liver microsomes as well as UGT1A9 and 2B7 (Hanioka et al., 2008). The mouse isoforms of UGT2B15 and UGT2B7 are Ugt2b35 and Ugt2b1, respectively. In pregnant mice, Ugt1a9, 2b1, and 2b35 mRNA expression was decreased at GD14 and/or 17 (Fig 1A). Therefore, BPA glucuronidation was used as a marker.
reaction to characterize Ugt activity. On GD14, in vitro BPA-glucuronide formation was significantly decreased by 30% in livers of pregnant mice compared to virgin controls (Fig 1C). There was no significant change in BPA-glucuronide formation between virgin and pregnant mice on GD17.

APAP is metabolized by UGT1A1, 1A6, 1A9, and 2B15 (Ugt35 in mice) in humans (Court et al., 2001; Mutlib et al., 2006). Down-regulation of mRNA and/or protein expression for 1a6 and 1a9 was found in the present study. Therefore, we also tested whether APAP glucuronidation in vitro was altered in S9 fractions from livers of pregnant mice. However, no significant differences in APAP-glucuronide generation were observed between pregnant dams and virgin controls after 30 to 120 min incubations (data not shown).

Hepatic Sult expression and function during pregnancy and lactation. Sults are cytosolic enzymes that are important in hormone regulation/metabolism and xenobiotic detoxification. Prior studies demonstrate marked gender differences in Sult mRNA expression (Alnouti and Klaassen, 2011). Because sex hormones are important in gender- divergent Sult levels, we hypothesized that pregnancy might alter their expression. Sult1a1, 2a1/2, and 3a1 mRNAs were increased 100% to 500% at various time points during pregnancy and lactation (Fig 2A, Table 1). Consistently, up-regulation of Sult1a1 protein expression was also found on GD14 and 17 (Fig 2B). Conversely, the mRNA expression of Sult1d1 was decreased 40 to 60% in dams during late pregnancy. Messenger RNA expression of all Sults returned to control levels in dams after weaning of pups.
In addition to Ugts, Sult1a1 is also involved in the conjugation of APAP in mice. During pregnancy, mRNA and protein expression of Sult1a1 were up-regulated in mice livers. Coordinately, these changes resulted in an increase of enzyme activity, evidenced by 20-40% higher APAP-sulfate formation in liver S9 fractions from pregnant mice on GD14 and 17 (Fig 2C).

**Hepatic Gst expression during pregnancy and lactation.** Gst enzymes conjugate chemotherapeutic drugs, insecticides, herbicides, and carcinogens with glutathione and also protect cellular macromolecules against electrophiles and products of oxidative stress (reviewed in Hayes et al., 2005). Similar to Ugts, Gsta1 and a4 mRNAs were reduced in livers of pregnant mice during mid- to late-gestation (Fig 3A, Table 1). In particular, Gsta1 and a4 mRNAs were decreased by 60 to 80% between GD14 and 17. A similar trend for down-regulation of Gsta4 protein expression was also observed although not statistically significant (Fig 3B). Gstp1 mRNA also decreased in pregnant mice during early gestation (GD7). Conversely, Gstm2 mRNA was increased on GD7 and PND15.

**Hepatic transcription factor expression and activity during pregnancy and lactation.** Phase-II enzymes are cross-regulated by AhR, CAR, PPARα, PXR, and Nrf2. Expression of each transcription factor was quantified on GD14 and 17. To assess changes in activity of each transcription factor, mRNA levels of prototypical target genes were also measured. Coinciding with maximal decreases in Ugts and Gsts, the mRNA expression of CAR, PXR and PPARα were down-regulated on either GD14 or 17. In contrast, the expression of AhR and Nrf2 mRNA was unchanged (Fig 4A). Consistently, mRNA and protein expression of Cyp2b10 (target gene of
CAR) and Cyp4a14 (target gene of PPARα) were decreased by 60-90% compared to their controls (Fig 4A and B). Cyp3a11, which is a target gene of PXR, was also decreased by 40% at the mRNA level on GD17, although no difference in Cyp3a protein was observed (Fig 4A and B). Of note, the antibody used for quantification of Cyp3a11 was anti-Cyp3a4/3a1/3a11. Thus, additional Cyp3a isoforms may be masking a potential decline in Cyp3a11 protein. No changes in Cyp1a1 mRNA (target gene of AhR) nor NAD(P)H quinone oxidoreductase 1 (Nqo1, target gene of Nrf2) were observed.

Hnf4α and Pgc-1α are important transcriptional regulators that can interact with several transcription factors, including PPARα and CAR, to regulate the expression of hepatic metabolic enzymes and transporters (Wortham et al., 2007; Jover et al., 2009; Lu et al., 2010). The mRNA level of Pgc-1α was dramatically decreased by 60% at GD14 (Fig 5). Hnf4α mRNA expression was not significantly changed in the livers of pregnant mice at GD14/17 (data not shown).

The mRNA level of ERα was increased to 200-400% on GD14 and 17 (Fig 5). The mRNA expression of ERβ and progesterone receptor was very low in mouse liver and changes in expression were undetectable during pregnancy (data not shown).
Discussion

The present study investigated the regulation of Phase-II enzyme mRNA, protein, and function during pregnancy and lactation in mice. We have demonstrated down-regulation of hepatic glucuronidation and up-regulation of sulfation during pregnancy that corresponds with time-dependent changes in mRNA expression of metabolism genes. We have further shown parallel decreases in the expression and activity of the transcription factors CAR, PPARα, and PXR as well as their co-activator Pgc-1α. In contrast, the expression of the hepatic ERα receptor was enhanced in pregnant mice. Taken together, CAR, PPARα, PXR, and ERα are candidate transcriptional pathways for the regulation of Phase-II metabolism during pregnancy, however, the exact contribution of each nuclear receptor needs to be tested directly.

Microarray analysis of livers from pregnant rats near parturition has demonstrated decreases in expression of several Phase-I enzymes, Phase-II enzymes including Ugt1a6 and 1a7, Gst alpha and mu genes, as well as the nuclear receptor CAR (He et al., 2007). In a separate study, it was shown that protein expression and enzyme activities of several Ugt isoforms were reduced in maternal rat livers in the absence of changes in mRNA (Luquita et al., 2001). As a result, post-translational regulation was suggested as a mechanism regulating Phase-II metabolism during pregnancy. We show coordinate decreases in Ugt and Gst mRNAs in a time-dependent manner. Therefore, we conclude that regulation of Ugt transcription in mice is likely to be the mechanism for protein and functional changes, and that prior rat studies may reflect differences between species or experimental design and strengthen the use of a time course in this study.
The transcription factors CAR and PXR often share similar xenobiotic responsive elements leading to an overlapping set of downstream genes (Wang and LeCluyse, 2003; Tolson and Wang, 2010). For example, Phase-II enzymes such as Ugt1a1, 1a6, 1a9, 2b1, 2b5 and Gsta1/2 are regulated by CAR and PXR activation in rodents (Chen et al., 2003; Maglich et al., 2004; Hayes et al., 2005; Buckley and Klaassen, 2009a; Tolson and Wang, 2010; Aleksunes and Klaassen, 2012). Consistently, in this study, these isoforms were down-regulated during pregnancy and corresponded with reduced CAR and PXR signaling.

PPARα is one of the key transcriptional pathways responsible for regulating hepatic lipid metabolism. Chemical activation of PPARα can induce some Ugts and Gsts (Alnouti and Klaassen, 2008; Knight et al., 2008). Similar to CAR and PXR, there is a down-regulation of PPARα mRNA in mouse liver during pregnancy, which may contribute to the regulation of Phase-II genes (Sweeney et al., 2006; Papacleovoulou et al., 2011). In addition to down-regulating nuclear receptors, pregnancy also reduces the mRNA expression of Pgc-1α, which is a transcription coactivator of PPAR signaling and a key regulator of cellular energy metabolism (Sweeney et al., 2006; Jover et al., 2009; Fig. 5). Several previous studies have also pointed to HNF4α as a transcriptional regulator of metabolic enzymes and transporters in the liver (Wortham et al., 2007; Jover et al., 2009; Lu et al., 2010). However, we observed no change in Hnf4α mRNA in pregnancy. Further research is needed to definitively demonstrate the mechanistic role of each transcription factor in regulating Phase-II genes during pregnancy.

Pregnancy causes high levels of circulating sex hormones. Serum estradiol and progesterone were maximally increased between GD14 and 17 (data not shown). Elevated levels of hormones
coupled with induction of ERα mRNA may be involved in the regulation of other nuclear receptors. A prior study demonstrated the down-regulation of PXR and CAR in estradiol benzoate-treated rats (Choi et al., 2011). In addition, Cyp2b10 (CAR target gene) is induced by estradiol and repressed by progesterone in primary mouse hepatocytes suggesting divergent regulation of this pathway by sex hormones (Kawamoto et al., 2000). Interestingly, CAR can inhibit ER-mediated signaling pathway by interfering with coactivators and direct interaction of ER and CAR in human hepatoma cells (Min et al., 2002). Therefore, increased estradiol and progesterone signaling may be one of possible mechanisms for modulating other nuclear receptor pathways during pregnancy.

The plasticizer BPA undergoes extensive glucuronidation in humans and is largely excreted in its conjugated form. In the present study, BPA glucuronidation was reduced in S9 fractions from livers of pregnant mice, which is likely due to down-regulation of Ugt2b1 and Ugt2b35 expression. Similar functional changes in BPA conjugation have been reported in microsomes from pregnant rat livers (Matsumoto et al., 2002). In addition, BPA-glucuronide excretion into bile is reduced in pregnant rats due to down-regulation of the multidrug resistance-associated protein 2 transporter (Inoue et al., 2005). It is likely that down-regulation of BPA glucuronidation and transport may be the mechanisms governing reduced biliary excretion of BPA during pregnancy in rodents. In contrast to BPA, glucuronidation of APAP did not significantly change in S9 fractions from pregnant mouse livers. Clinically, the oral clearance of APAP has been reported to be 58% higher in the pregnant women compared to non-pregnant women of comparable age and attributed to increased Ugt activity (Miners et al., 1986). It is unknown if this contradictory finding is due to differential regulation between species or APAP
concentrations selected. Nonetheless, additional studies are needed to test the effects of pregnancy on the Phase-II metabolism of specific chemicals and drugs.

The majority of Ugt isoforms were down-regulated in livers of pregnant mice, with the exception of Ugt1a5. In pregnant mice, Ugt1a5 mRNA increased 50 to 100% during mid- to late gestation (Fig. 1A). Ugt1a5 mRNA has been shown to be markedly induced in livers of hypophysectomized female mice treated with estradiol (Buckley and Klaassen, 2009b). Furthermore, it has been demonstrated that the human ortholog of Ugt1a5, UGT1A4 is up-regulated by 17β-estradiol in human hepatoma cells via the estrogen receptor and specificity protein 1 transcription factor (Chen et al., 2009). Moreover, the up-regulation of this UGT isoform is suggested to be responsible for enhanced clearance of the antiseizure drug lamotrigine during pregnancy (Tran et al., 2002; de Haan et al., 2004; Pennell et al., 2004). Because estradiol levels are elevated in pregnancy, direct stimulation of Ugt1a5 transcription by estradiol may explain the regulation of this gene in an opposing direction to other Ugts.

Increased Sult mRNA expression during pregnancy may be due to the stimulatory effects of sex hormones. For example, exogenous administration of 17β-estradiol to female mice that have undergone either hypophysectomy or gonadectomy induces hepatic expression of Sult2a1/2 and 3a1 mRNA (Alnouti and Klaassen, 2011). Likewise, the rat Sult1a1 promoter is transactivated in hepatocytes in vitro in response to treatment with the glucocorticoid, dexamethasone (Duanmu et al., 2001). Glucocorticoid and androgen receptors also activate the same region of the Sult1a1 promoter in cultured hepatocytes (Fang et al., 2003). Because glucocorticoids, androgens, and progesterone share the same hormone response element (an inverted repeat separated by 3
nucleotides) (Ham et al., 1988; Beato, 1989; Fang et al., 2003), elevated progesterone concentrations may be involved in up-regulation of Sult1a1 mRNA in pregnant mouse livers.

It is well known that the plasma concentrations of some drugs change during pregnancy. However, most of these clinical reports are related to CYP-mediated metabolism of drugs (Anderson, 2005). Information regarding pregnancy-induced pharmacokinetic changes of Phase-II-metabolized drugs is limited. Clinical pharmacokinetic changes in lamotrigine, zidovudine, morphine, and oxazepam disposition have been attributed to altered Phase-II metabolism during pregnancy (Anderson, 2005). UGT2B7 and 2B15 up-regulation has been proposed as the mechanism responsible for the increased clearance of zidovudine, morphine, and oxazepam in pregnant women (Tomson et al., 1979; Gerdin et al., 1990; Watts et al., 1991; O'Sullivan et al., 1993). Likewise, the oral clearance of labetalol is increased in pregnant women (Rogers et al., 1990). Further investigation has suggested a potential role for progesterone in regulating labetalol elimination by modulating the hepatic expression and function of UGT1A1 during pregnancy (Jeong et al., 2008). Conversely, we observed down-regulation of Ugt1a1 mRNA during pregnancy in the present study, suggesting that this isoform may be differentially regulated between species. Therefore, extrapolation of rodent data from developmental toxicity studies to humans should be done cautiously because of potential differences in maternal metabolism and clearance.

The hepatic mRNA expression of Ugts and Gsts and their upstream transcription factors CAR, PXR, and PPARα were down-regulated in parallel in mice during pregnancy. In addition, enhanced levels of Ugt1a5 mRNA and various Sult isoforms as well as ERα were observed.
However, to more definitively demonstrate the mechanistic link between altered expression of transcriptional factors and metabolic enzymes, additional experiments such as direct treatment of hepatocytes with sex hormones and gene knockout/knockdown studies are needed. Collectively, changes in Phase-II metabolism may alter chemical disposition and the likelihood of fetal drug exposure during pregnancy.
Acknowledgements

The authors would like to thank Dr. Curtis Klaassen (University of Kansas Medical Center) for providing total RNA for the time-course experiment and a number of bDNA probes, Dr. Nathan Cherrington (University of Arizona) and Dr. Jason Richardson (UMDNJ-Robert Wood Johnson Medical School) for providing antibodies, Dr. Jose Manautou (University of Connecticut) for APAP authentic standards, and graduate students and fellows of the Aleksunes laboratory for their contributions to this project.
Authorship Contributions

Participated in research design: Wen, Aleksunes

Conducted experiments: Wen, Donepudi

Contributed new reagents or analytic tools: Slitt, Thomas, King

Performed data analysis: Wen, Donepudi

Wrote or contributed to the writing of the manuscript: Wen, Aleksunes
References


Buckley DB and Klaassen CD (2009a) Induction of mouse UDP-glucuronosyltransferase mRNA expression in liver and intestine by activators of aryl-hydrocarbon receptor, constitutive
androstane receptor, pregnane X receptor, peroxisome proliferator-activated receptor
alpha, and nuclear factor erythroid 2-related factor 2. Drug Metab Dispos 37:847-856.

Buckley DB and Klaassen CD (2009b) Mechanism of gender-divergent UDP-
glucuronosyltransferase mRNA expression in mouse liver and kidney. Drug Metab
Dispos 37:834-840.

Chen C, Staudinger JL and Klaassen CD (2003) Nuclear receptor, pregnane X receptor, is
required for induction of UDP-glucuronosyltranferases in mouse liver by pregnenolone-
16 alpha-carbonitrile. Drug Metab Dispos 31:908-915.

Chen H, Yang K, Choi S, Fischer JH and Jeong H (2009) Up-regulation of UDP-
glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of
increased lamotrigine elimination in pregnancy. Drug Metab Dispos 37:1841-1847.

Choi SY, Fischer L, Yang K, Chung H and Jeong H (2011) Isoform-specific regulation of
cytochrome P450 expression and activity by estradiol in female rats. Biochem Pharmacol
81:777-782.

Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO and Mackenzie PI
(2001) Interindividual variability in acetaminophen glucuronidation by human liver
microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase

Cui JY, Choudhuri S, Knight TR and Klaassen CD (2010) Genetic and epigenetic regulation and
expression signatures of glutathione S-transferases in developing mouse liver. Toxicol Sci


Howie D, Adriaenssens PI and Prescott LF (1977) Paracetamol metabolism following
overdosage: application of high performance liquid chromatography. *J Pharm Pharmacol*

Bisphenol a glucuronidation and excretion in liver of pregnant and nonpregnant female

Jeong H (2010) Altered drug metabolism during pregnancy: hormonal regulation of drug-

Jeong H, Choi S, Song JW, Chen H and Fischer JH (2008) Regulation of UDP-
glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol

genes by the nuclear receptor hepatocyte nuclear factor 4-alpha. *Curr Drug Metab*
10:508-519.

Kawamoto T, Kakizaki S, Yoshinari K and Negish M (2000) Estrogen activation of the nuclear
orphan receptor CAR (constitutive active receptor) in induction of the mouse Cyp2b10

in male mice by prototypes of various classes of microsomal enzyme inducers. *Toxicol

and Cherrington NJ (2007) Efflux transporter expression and acetaminophen metabolite
excretion are altered in rodent models of nonalcoholic fatty liver disease. *Drug Metab Dispos* **35:**1970-1978.


Footnotes

This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases [Grant DK080774] and the National Institute of Environmental Health Sciences [Grants ES020522, ES016042, ES005022], components of the National Institutes of Health.

Reprint Requests

Lauren M. Aleksunes, Pharm.D., Ph.D.
Department of Pharmacology and Toxicology
Rutgers, the State University of New Jersey
Ernest Mario School of Pharmacy
170 Frelinghuysen Road
Piscataway, NJ 08854
Phone: (848) 445-5518
E-mail: aleksunes@eohsi.rutgers.edu
Legends for Figures

Figure 1. Expression and activity of hepatic Ugts in pregnant mice. (A) Messenger RNA expression of Ugt1a1, 1a5, 1a6, 1a9, 2a3, 2b1, 2b5, 2b34 and 2b35 was quantified by the bDNA assay in time-matched pregnant and virgin control mice at various gestational and postnatal days. Data was normalized to virgin mice (set to 1.0) and presented as mean ± SE (n=3-4). (B) Protein expression of Ugt1a1, 1a6, 1a9 and 2b34 was quantified by Western blotting analysis in time-matched pregnant (GD14 and 17) and virgin mice (n=3). (C) Bisphenol A (BPA, 1 μM) was incubated with mouse liver S9 fractions isolated from time-matched pregnant (GD14 and 17) and virgin mice for 30 min in the presence of the cofactor UDPGA (n=5-6). Asterisks (*) represent statistically significant differences (p < 0.05) compared to time-matched virgin mice.

Figure 2. Expression and activity of hepatic Sults in pregnant mice. (A) Messenger RNA expression of Sult1a1, 2a1/2, 1d1 and 3a1 was quantified by the bDNA assay in time-matched pregnant and virgin mice at various gestational and postnatal days. Data was normalized to virgin mice (set to 1.0) and presented as mean ± SE (n=3-4). (B) Protein expression of Sult1a1 and 2a1 was quantified by Western blotting analysis in time-matched pregnant (GD14 and 17) and virgin mice (n=3). (C) APAP (2 mM) was incubated with mouse liver S9 fractions isolated from time-matched pregnant (GD14 and 17) and virgin mice for 30 min in the presence of the cofactor PAPS (n=5-6). Asterisks (*) represent statistically significant differences (p < 0.05) compared to time-matched virgin mice.

Figure 3. Expression of hepatic Gsts in pregnant mice. (A) Messenger RNA expression of Gsta1, a4, m2 and p1 was quantified by the bDNA assay in time-matched pregnant and virgin
mice at various gestational and postnatal days. Data were normalized to virgin mice (set to 1.0) and presented as mean ± SE (n=3-4). (B) Protein expression of Gsta1 and a4 was quantified by Western blotting analysis in time-matched pregnant (GD14 and 17) and virgin mice (n=3). Asterisks (*) represent statistically significant differences (p < 0.05) compared to time-matched virgin mice.

**Figure 4. Expression of hepatic transcriptional factors and prototypical target genes.** (A) Messenger RNA expression of AhR, CAR, PXR, PPARα, and Nrf2 and their target genes Cyp1a1, 2b10, 3a11, 4a14, and Nqo1 was quantified by the bDNA assay in time-matched pregnant (GD14 and 17) and virgin mice. Data were normalized to virgin mice (set to 1.0) and presented as mean ± SE (n=3-4). (B) Protein expression of Cyp1a1, 2b10, 3a11, 4a14, and Nqo1 was quantified by Western blotting analysis in time-matched pregnant (GD14 and 17) and virgin mice (n=3). Asterisks (*) represent statistically significant differences (p < 0.05) compared to time-matched virgin mice.

**Figure 5. Messenger RNA expression of hepatic Pgc-1α and ERα in pregnant mice.** Messenger RNA expression of Pgc-1α and ERα was quantified by qPCR in time-matched pregnant (GD14 and 17) and virgin mice. Data were normalized to virgin mice (set to 1.0) and presented as mean ± SE (n=3-4). Asterisks (*) represent statistically significant differences (p < 0.05) compared to time-matched virgin mice.
Table 1. Summary of Phase-II enzyme and transcription factor-related mRNA changes in the livers of mice during pregnancy and lactation.\(^1\)

<table>
<thead>
<tr>
<th></th>
<th>Pregnancy</th>
<th>Lactation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Days 7 11</td>
<td>15 30</td>
</tr>
<tr>
<td><strong>Ugts</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ugt1a1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Ugt1a5</td>
<td>↑↑</td>
<td>↑↑</td>
</tr>
<tr>
<td>Ugt1a6</td>
<td>-</td>
<td>↓↓</td>
</tr>
<tr>
<td>Ugt1a9</td>
<td>-</td>
<td>↓↓</td>
</tr>
<tr>
<td>Ugt2a3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Ugt2b1</td>
<td>-</td>
<td>↓↓</td>
</tr>
<tr>
<td>Ugt2b5</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Ugt2b34</td>
<td>-</td>
<td>↓↓</td>
</tr>
<tr>
<td>Ugt2b35</td>
<td>-</td>
<td>↓↓</td>
</tr>
<tr>
<td><strong>Sults</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sult1a1</td>
<td>↑↑</td>
<td>↑↑</td>
</tr>
<tr>
<td>Sult2a1/2</td>
<td>↑↑</td>
<td>↑↑</td>
</tr>
<tr>
<td>Sult1d1</td>
<td>-</td>
<td>↓↓</td>
</tr>
<tr>
<td>Sult3a1</td>
<td>-</td>
<td>↑↑</td>
</tr>
<tr>
<td><strong>Gsts</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gsta1</td>
<td>-</td>
<td>↓↓</td>
</tr>
<tr>
<td>Gsta4</td>
<td>-</td>
<td>↓↓</td>
</tr>
<tr>
<td>Gstm2</td>
<td>↑↑</td>
<td>-</td>
</tr>
<tr>
<td>Gstp1</td>
<td>↓↓</td>
<td>-</td>
</tr>
<tr>
<td><strong>Signaling</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AhR</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>CAR</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>PXR</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>PPARα</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Nrf2</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>ERα</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Pgc-1α</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Cyp1a1</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Cyp2b10</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Cyp3a11</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Cyp4a14</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Nqo1</td>
<td>ND</td>
<td>ND</td>
</tr>
</tbody>
</table>

\(^1\) Statistically significant changes are designated as ↑↑ or ↓↓. Minus signs (-) represent no significant change and ND represents not determined.
Fig 1.
Fig 2.
Fig 3.
A.

**AHF**

- **AhR**
- **CAR**
- **PXR**
- **PPARα**
- **Nrf2**

**CYP1A1**

- **CYP2B10**
- **CYP3A11**
- **CYP4A14**
- **NQO1**
- **β-Actin**

Relative mRNA Expression

- **Day 14**
- **Day 17**

B.

**Day 14**

- **Virgin**
- **Pregnant**

**Day 17**

- **Virgin**
- **Pregnant**

**CYP1A1**

**CYP2B10**

**CYP3A11**

**CYP4A14**

Relative Protein Expression

- **Day 14**
- **Day 17**

**NQO1**

**Day 14**

**Day 17**

**Fig 4.**